Medical Devices · NYSE: SYK
Stryker earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 28 Jan 2027
Latest: Q3 2026
Stryker became exclusive U.S. sales agent for CMR Surgical's Versius robot, a first step into soft-tissue robotics, while a hip and knee slowdown and execution distractions held back orthopaedics.
Mako-related demand was strong, with Ortho Tech and Endoscopy leading growth. Hip and knee procedures slowed, driven by affordability concerns and more pre-authorization denials. Stryker also did not win share at its usual pace, with the cyber incident and an SAP rollout distracting its orthopaedics sales teams. Peripheral vascular improved as supply recovered, helped by a one-time payment from a China joint venture. Capital equipment demand stayed strong, and Stryker closed the ZuriMed acquisition for rotator cuff repair.
Quarters
KPI history
Data
| Q4 2024 | $6.4B |
| Q1 2025 | $5.9B |
| Q2 2025 | $6.0B |
| Q3 2025 | $6.1B |
| Q4 2025 | $7.2B |
| Q1 2026 | $6.0B |
| Q2 2026 | $6.6B |
| Q3 2026 | $6.5B |
Data
| Q4 2024 | $1.41 |
| Q1 2025 | $1.69 |
| Q2 2025 | $2.29 |
| Q3 2025 | $2.22 |
| Q4 2025 | $2.20 |
| Q1 2026 | $1.93 |
| Q2 2026 | $3.30 |
| Q3 2026 | $1.96 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 9.0% |
| Q1 2025 | 14.3% |
| Q2 2025 | 18.5% |
| Q3 2025 | 18.7% |
| Q4 2025 | 25.2% |
| Q1 2026 | 15.5% |
| Q2 2026 | 25.2% |
| Q3 2026 | 15.9% |
Data
| Q4 2024 | $1.7B |
| Q1 2025 | $127.0M |
| Q2 2025 | $928.0M |
| Q3 2025 | $1.4B |
| Q4 2025 | $1.9B |
| Q1 2026 | $415.0M |
| Q2 2026 | $1.1B |
| Q3 2026 | $1.2B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4B | $5.9B | $6.0B | $6.1B | $7.2B | $6.0B | $6.6B | $6.5B |
| Gross margin | 64.9% | 63.8% | 63.8% | 63.6% | 64.5% | 63.3% | 68.3% | 65.2% |
| Operating income | $581.0Md | $837.0M | $1.1B | $1.1B | $1.8Bd | $936.0M | $1.7B | $1.0B |
| Operating margin | 9.0% | 14.3% | 18.5% | 18.7% | 25.2% | 15.5% | 25.2% | 15.9% |
| Net income | $546.0M | $654.0M | $884.0M | $859.0M | $849.0M | $745.0M | $1.3B | $753.0M |
| Diluted EPS | $1.41 | $1.69 | $2.29 | $2.22 | $2.20 | $1.93 | $3.30 | $1.96 |
| Operating cash flow | $1.9Bd | $250.0M | $1.1Bd | $1.5Bd | $2.1Bd | $581.0M | $1.3Bd | $1.5Bd |
| Capital expenditure | $266.0Md | $123.0M | $183.0Md | $187.0Md | $268.0Md | $166.0M | $202.0Md | $237.0Md |
| Free cash flow | $1.7B | $127.0M | $928.0M | $1.4B | $1.9B | $415.0M | $1.1B | $1.2B |
| R&D expense | $358.0Md | $405.0M | $407.0M | $410.0M | $401.0Md | $413.0M | $434.0M | $433.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 30 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 31 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 11 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 11 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 31 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 2 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 12 Feb 202510-K for the period ended 31 Dec 2024SEC ↗